help button home button JAMIA Hate scrolling?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
First published June 25, 2008 as JAMIA PrePrint; doi:10.1197/jamia.M2605
Journal of the American Medical Informatics Association 2008;15(5):581-584
© 2008 American Medical Informatics Association

A more recent version of this article appeared on September 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
M2605v1
15/5/581    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kim, D.
Right arrow Articles by Holliday, S. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.
Right arrow Articles by Holliday, S. H.

Submitted on August 22, 2007
Accepted on June 6, 2008

Opportunities for Electronic Health Record Data to Support Business Functions in the Pharmaceutical Industry - A Case Study from Pfizer, Inc.

Daijin Kim MBA1*, Steven Labkoff MD1, and Samuel H. Holliday2

Affiliation of the authors: 1 Healthcare Informatics, Pfizer Inc., New York, NY; 2 Accenture, Philadelphia, PA

* To whom correspondence should be addressed.

The Pfizer Healthcare Informatics team conducted a series of guided interviews with 35 Pfizer senior leaders to elicit their understanding, desires and expectations of how Electronic Health Records (EHR) might be used in the pharmaceutical industry today and/or in the future. The interviews yielded fourteen use case categories comprising 42 specific use cases. The highest priority use case were "Drug Safety & Surveillance", "Clinical Trial Recruitment", and "Support Regulatory Approval". Fifteen EHR companies were surveyed to assess their functionality against the specified use cases. Self-reported responses from the EHR companies were highest for "Virtual Phase IV Trials" and "Document Management for Clinical Trials". This research identifies preliminary opportunities for EHR products to provide aggregate, blinded data to address the interests of the pharmaceutical industry. However, further collaboration between the stakeholders will be necessary to ensure the full realization of the opportunities for data re-use.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 1994 by the American Medical Informatics Association.